

Supplementary Table 1: Baseline characteristics for the three center populations

Characteristics	Overall(N=3277)	Yanghu Center(N=1489)	Chengzhong Center(N=1169)	Xuzhou Center(N=619)
Age, years	64.60±13.91	62.97±13.88	65.72±13.93	66.44±13.53
Male, n (%)	2458(75.0)	1174(78.8)	841(71.9)	443(71.6)
Body mass index, kg/m ²	24.28±3.68	24.80±3.55	24.23±3.64	23.15±3.81
Current or former smoker, n (%)	1561(47.6)	663(44.5)	591(50.6)	307(49.6)
Alcohol consumption, n (%)	370(11.3)	163(10.9)	132(11.3)	75(12.1)
Hypertension, n (%)	2176(66.4)	978(65.7)	773(66.1)	425(68.7)
Diabetes, n (%)	1104(33.7)	578(38.8)	362(31.0)	164(26.5)
STEMI, n (%)	1973(60.2)	867(58.2)	668(57.1)	438(70.8)
NSTEMI, n (%)	1304(39.8)	622(41.8)	501(42.9)	181(29.2)
Killip class >2, n (%)	405(12.4)	213(14.3)	115(9.8)	77(12.4)
Heart rate, bpm	80.09±15.72	79.87±14.95	79.32±16.17	82.07±16.51
WBC, 10 ⁹ /L	9.18(7.23-11.8)	9.38(7.49-12.07)	9.05(7.01-11.43)	8.97(7.02-11.61)
Neutrophil percentage, %	73.42±12.03	71.85±12.62	74.01±11.72	76.08±10.47
Aspirin	3186(97.2)	1451(97.4)	1121(95.9)	614(99.2)
Clopidogrel	949(29.0)	317(21.3)	197(16.9)	435(70.3)
Ticagrelor	2301(70.2)	1148(77.1)	968(82.8)	185((29.9)
ACEI/ARB	2089(63.7)	970(65.1)	720(61.6)	399(64.5)
β-blocker	2096(64.0)	965(64.8)	806(68.9)	325(52.5)
Statins	3110(94.9)	1479(99.3)	1025(87.7)	606(97.9)
Tirofiban hydrochloride	1591(48.6)	756(50.8)	544(46.5)	291(47)

STEMI, ST-elevation myocardial infarction; NSTEMI, Non-ST-elevation myocardial infarction;
 BMI, body mass index; WBC, white blood cell; ACEI/ARB, angiotensin-converting enzyme
 inhibitors/angiotensin receptor blockers.